Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer

Area of Science:

• Oncology
• Immunotherapy

Background:

• Recurrent and resistant uterine cancer presents a significant clinical challenge with limited therapeutic avenues.
• The PD-1 inhibitor, pembrolizumab, has gained FDA approval for MMR-deficient solid tumors, including uterine cancer, offering a new treatment modality.

Purpose of the Study:

• To evaluate the efficacy and safety of pembrolizumab in patients with recurrent, resistant uterine cancer.
• To assess the potential for long-term durable responses in refractory endometrial cancer.

Main Methods:

• Retrospective analysis of patients with recurrent, resistant uterine cancer treated with pembrolizumab.
• Evaluation of response rates, duration of response, and adverse events.

Main Results:

• Pembrolizumab demonstrated significant efficacy in patients with recurrent, resistant uterine cancer.
• The treatment resulted in long-term durable responses in a subset of patients with refractory endometrial cancer.
• Pembrolizumab exhibited a favorable safety profile with minimal side effects.

Conclusions:

• Pembrolizumab represents a viable and effective treatment option for patients with recurrent, resistant uterine cancer.
• Durable responses and good tolerability suggest pembrolizumab's potential to improve outcomes in this patient population.